Mobidiag is a Finnish-French biotechnology company specializing in developing and marketing innovative solutions for molecular diagnostics of infectious diseases. Established in 2000, Mobidiag has served the European clinical diagnostics market with its multiplex Prove-it™ product family since 2008. In 2013, Mobidiag merged with a diagnostic platform developer Genewave and a stool-based clinical assay development company Amplidiag, complementing our capabilities in developing and offering industry-leading diagnostic solutions and solidifying our position in the field of molecular diagnostics.
Mobidiag’s Amplidiag® product line encompasses multiplex diagnostic tests for gastrointestinal infections. The products use well-established multiplex real-time PCR technology, ensuring optimal performance, suitability for high-volume screening use and cost-effectiveness in mid-sized to large laboratory settings. Mobidiag’s upcoming Novodiag® platform will set a new benchmark to automated, integrated molecular diagnostics, allowing on-demand targeted and syndromic testing.
Our mission is to address the unmet need for high information-density, affordable molecular diagnostic tools to enable the rapid treatment and triage of patients at the point of impact. We want to improve the quality and efficiency of healthcare and aid in the combat against spreading and emerging antimicrobial resistances. Our multi-disciplinary team of experts is dedicated to serving this mission and making an impact, and we work closely with distinguished clinical, academic and industrial partners to deliver highest-value solutions to our customers throughout the world.